NATCO Pharma Launches Generic Semaglutide Injection in India Post-Patent Expiry

Bias Analysis: The articles primarily present a business and healthcare perspective without political framing. They focus on NATCO Pharma's product launch, regulatory approvals, and pricing details. There is no evident political bias, as the coverage centers on market developments and medical treatment options, reflecting neutral corporate and regulatory viewpoints.

Sentiment: The overall tone across the articles is positive, highlighting NATCO Pharma's market entry with an affordable diabetes treatment. The coverage emphasizes product availability, pricing advantages, and regulatory approval, conveying a constructive outlook on increased access to medication without critical or negative commentary.

Lens Score: 33/100 — Story is well-covered by media outlets. Public interest: 0/100. Coverage gap: 100%.